Purpose: To design a fluorine MRI/MR spectroscopy approach to quantify renal vascular damage after ischemia-reperfusion injury, and the therapeutic response to antithrombin nanoparticles (NPs) to protect kidney function. Methods: A total of 53 rats underwent 45 min of bilateral renal artery occlusion and were treated at reperfusion with either plain perfluorocarbon NPs or NPs functionalized with a direct thrombin inhibitor (PPACK:phenyalanine-proline-arginine-chloromethylketone). Three hours after reperfusion, kidneys underwent ex vivo fluorine MRI/MR spectroscopy at 4.7 T to quantify the extent and volume of trapped NPs, as an index of vascular damage and ischemia-reperfusion injury. Microscopic evaluation of structural damage and NP trapping in non-reperfused renal segments was performed. Serum creatinine was quantified serially over 7 days. Results: The damaged renal cortico-medullary junction trapped a significant volume of NPs (P ¼ 0.04), which correlated linearly (r ¼ 0.64) with the severity of kidney injury 3 h after reperfusion. Despite global large vessel reperfusion, nonreperfusion in medullary peritubular capillaries was confirmed by MRI and microscopy, indicative of continuing hypoxia due to vascular compromise. Treatment of animals with PPACK NPs after acute kidney injury did not accelerate kidney functional recovery. Conclusions: Quantification of ischemia-reperfusion injury after acute kidney injury with fluorine MRI/MR spectroscopy of perfluorocarbon NPs objectively depicts the extent and severity of vascular injury and its linear relationship to renal dysfunction. The lack of kidney function improvement after early posttreatment thrombin inhibition confirms the rapid onset of ischemia-reperfusion injury as a consequence of vascular damage and non-reperfusion. The prolongation of medullary ischemia renders cortico-medullary tubular structures susceptible to continued necrosis despite restoration of large vessel flow, which suggests limitations to acute interventions after acute kidney injury, designed to interdict renal tubular damage.
INTRODUCTION
Microvascular injury in acute ischemic kidney injury (AKI) is proposed to play a critical role in the progression to chronic renal dysfunction and fibrosis (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . A technical hurdle to the mechanistic evaluation of peritubular capillary damage and assessment of novel vascularly targeted therapeutic interventions in AKI is the lack of objective functional and quantitative assays for defining the severity and extent of endothelial damage that may lead to persistent perfusion deficits and capillary rarefaction after ischemia-reperfusion injury. Current image-based methods such as X-ray microangiography require iodinated contrast agents that are nephrotoxic under conditions of AKI, as is also true for MRI studies using certain gadolinium-based contrast agents that are contraindicated at low glomerular filtration rates (11, 12) . We propose that further development of in vivo functionalimaging approaches for quantifying vascular damage that are potentially translatable to clinical environments would be of special interest for studying vascular causes of kidney dysfunction and for examining the efficacy of novel pharmaceutical candidates for AKI and/or chronic kidney disease.
To address these concerns, we have proposed a quantitative MRI method that uses a nonnephrotoxic, semipermeable contrast agent and perfluorocarbon-core (PFC) nanoparticles (NPs), which have been validated to date for quantification of endothelial barrier disruption in experimental atherosclerosis and AKI (13) (14) (15) . These agents have previously been used clinically as approved blood substitutes and manifest no apparent renal toxicity (16, 17) . Moreover, the abundant naturally occurring fluorine ( 19 F) in the core provides a unique and quantifiable spectral MR spectroscopy (MRS) signature with no obscuring background signal for rapid in vivo detection by MRI/MRS on clinical MRI platforms (18) (19) (20) . Circulating semipermeant PFC NPs are too large ($200 nm) to traverse intact vascular barriers, but under conditions of inflammation and endothelial damage can penetrate into the interstitium through breeched vascular barriers after 60-to 120-min circulation in vivo, where they remain trapped for detection and quantification by routine fluorine MRI/MRS methods (14) . Importantly, PFC NPs can also serve as dual purpose "theranostic" agents by carrying a variety of active pharmacological ingredients to molecularly targeted sites (21, 22) .
We recently reported that rodents undergoing AKI pretreated with thrombin-targeted PFC NPs loaded with antithrombin moieties (phenylalanine-proline-argininechloromethyl ketone (PPACK)) experience reduced thrombin deposition, attenuated microvascular injury, and hastened recovery of renal function, which was correlated with the extent of endothelial barrier disruption as detected nondestructively by 19 F MRI/MRS (15) . Accordingly, these and other studies (15, (23) (24) (25) (26) (27) implicate activated thrombin as a key pharmacological target for preventing early vascular damage in AKI. Moreover, thrombin may also serve as a molecular imaging target for high-resolution quantification of microvascular damage (19, 28) .
However, rigorous validation of PFC NPs as potential theranostic agents for AKI must first address several unanswered questions of translational significance. First, the relationship between the severity of acute renal injury and magnitude of the 19 F signal emanating from damaged microvasculature after NP trapping in disrupted microvessels is unknown. A corollary question involves the necessity for using molecularly targeted (e.g., thrombin) versus untargeted PFC NP to delineate microvascular damage, as we have shown previously in atherosclerotic mouse models that nontargeted nanostructures suffice for longitudinal quantification of endothelial barrier disruption (13) . Second, an evaluation of post-injury therapy with antithrombin NPs is lacking. Such data would help to better understand the kinetics of thrombin's deleterious consequences and whether renal ischemia-reperfusion injury might be preventable by thrombin inhibition if applied after AKI ensues. Accordingly, we studied rats undergoing 45 min of bilateral renal artery occlusions that were treated after injury with PPACK PFC NPs, and followed serially for 1 week to address these questions.
METHODS

Nanoparticle Formulation
Perfluorocarbon NPs ($200 nm) were formulated with either perfluorooctylbromide (PFOB) or perfluoro-15-crown-5-ether (CE), as previously described (28) . The use of two different emulsions in certain studies allows us to examine separately the effects and distributions of NPs at two different time points in the time course of AKI: pre-AKI and post-AKI. The PFOB emulsion consisted of 20% (v/v) of PFOB (Exfluor Research Corp, Round Rock, Texas, USA), 2.0% (w/v) of a surfactant commixture (99.9 mole% egg yolk phosphotidylcholine (Avanti Polar Lipids, Alabaster, Alabama, USA), and 0.1 mole% 1,2-distearoyl-sn-glyce-ro-3-phosphoethanolamine-N-(carboxy[polyethylene glycol]-2000) (Avanti Polar Lipids), and 1.7% (w/v) glycerin, with water comprising the balance.
The PFOB emulsion contained NPs with a zeta potential of 27.33 mV and a diameter of 202.3 nm. The CE emulsion consisted of 20% (v/v) of CE (Exfluor Research Corp), 2.0% (w/v) of the same surfactant commixture, and 1.7% (w/v) glycerin, with water comprising the balance. The CE emulsion contained NPs with a zeta potential of 20.12 mV and a diameter of 176.0 nm. For therapeutic interventions, antithrombin PPACK was conjugated to 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-N-(carboxy[polyethylene glycol]-2000) within the PFOB NP formulation using previously reported methods that enabled loading of approximately 13,650 PPACK moieties per particle (28) . Rhodamine (0.1 mol%) and fluorescein isothiocyanate (FITC) (0.6 mol%) labeled phospholipids were mixed into the PFOB and CE NP formulations, respectively, to render the PFC NP fluorescent.
Acute Kidney Injury Protocol
A total of 53 adult male Sprague Dawley rats (325-350 g) acquired from Harlan Laboratories (Indianapolis, Indiana, USA) were used in these studies, and all procedures were approved by the Animal Studies Committee of Washington University in St. Louis, Missouri, USA. Animals underwent laparotomy to produce 45 min of bilateral warm ischemia followed by reperfusion. Briefly, rats were anesthetized with a dose of ketamine (85 mg/Kg) and xylazine (10 mg/Kg) cocktail. A midline abdominal incision was then performed to expose the kidneys. Kidney ischemia was induced with the use of occlusive clips situated around the isolated renal artery. Successful cessation of renal blood flow was confirmed visually by change of the kidney color from pink to dark purple. Animal body temperature was maintained at 37 C using a small animal heating system. The occlusion was released after 45 min to restore kidney blood flow, which was confirmed by the change of kidney color to pink. The surgical wound was then closed in layers and the animal recovered and returned to the cage. Shamoperated animals were prepared for the 45-min laparotomy procedure, except renal arteries were not occluded. Upon euthanasia, rats were perfused with saline (0.9%) via left ventricular cannulation for 5 to 10 min at a pressure of 80 to 100 mgHg to wash out any circulating, nontrapped PFC NP. The left kidney was extracted and fixed in 10% formalin for 48 h followed by 19 F MRI. The right kidney was snap frozen and later sectioned at 8-mm thickness and prepared for histological analyses.
Treatment Protocols
We first sought to examine the effect of PPACK PFC NP on renal injury when treatment is given after AKI has developed (Fig. 1) . Before renal artery occlusion, plain (nontargeted) CE NPs were injected intravenously into the tail vein at 30 min before the occlusion (2 mL/kg). These NPs served as a 19 F MRI marker for assessing intrarenal, non-reperfused regions after AKI. Then, either PPACK PFOB NPs (N ¼ 9) or plain PFOB NPs (N ¼ 12) were injected intravenously into the tail vein at the time of kidney reperfusion (1 mL/kg), to compare active versus placebo agent responses. A sham surgical procedure without occlusion was performed in five mice with CE NPs injected before AKI and PFOB NPs injected 45 min later, before abdominal closure. Animals were survived for 7 days before euthanasia and further analysis.
We next sought to study the intrarenal distributions of PFC NPs as a function of timing of NP delivery (pre-versus post-AKI delivery) and the treatment (PPACK versus plain NP) to test for differences in particle access to tissue compartments. All animals were dosed with CE NPs 30 min before AKI. For posttreatment after AKI, one group received plain PFOB NPs (N ¼ 4) and another PPACK PFOB NPs (N ¼ 5) at the time of reperfusion. A sham surgical procedure was also performed as previously (N ¼ 3). Rats were euthanized 3 h following AKI, and kidneys were excised for PFOB versus CE 19 F MRI/ MRS.
To compare pre-AKI versus post-AKI NP trapping with MRI and the effect of the two different PFC cores on intrarenal trapping, a second group of rats received reversed dosing: plain PFOB NPs before AKI and CE NPs after AKI (N ¼ 12). Only plain NPs were used in these experiments. To plot and evaluate the quantitative data, the pretreatment-to--to-posttreatement ratio of 2:1 was normalized by dividing the concentration of pretreatment NPs by 2. To evaluate microscopic localization of PFC NPs, another group of animals were dosed with rhodamine-labeled PFOB NPs 30 min before AKI and FITC-labeled CE NPs after AKI (N ¼ 3), at the time of reperfusion, for fluorescent microscopy imaging.
Serum Creatinine Level
Blood samples (200 mL) were collected before the procedure and at the time of euthanization for all rats. For rats in the longitudinal study, additional blood samples were collected at 6 h, 1, 2, and 3 days after AKI. Blood was centrifuged and serum creatinine concentration (mg/dL) was analyzed using an AMS LIASYS 330 clinical chemistry system (AMS Diagnostics, Wichita, Kansas, USA) at the DCM Research Animal Diagnostic Laboratory, Washington University in St. Louis School of Medicine (St. Louis, Missouri, USA).
F MRI/MRS
All MRI experiments were carried out on a 4.7T Varian scanner (Varian Medical Systems Inc, Palo Alto, California, USA) using a solenoid transmit-receive radiofrequency coil (2-cm inner diameter). The kidney was then placed in the solenoid coil, and a tube of 4% trifluoroacetic acid (10 mL) was placed next to the kidney as an external standard for calibration of the kidney 19 F signal. The coil was first tuned to 1 s; echo time (TE) ¼ 15 ms; number of transients (nt) ¼ 4) were acquired to locate a central slice that bisects the kidney. The coil was then turned to 19 F frequency (189.6 MHz) and a fluorine spectrum (TR ¼ 2 s; nt ¼ 128) from the whole kidney was acquired over 4 min to quantify the amount of trapped PFOB and CE NPs, respectively (20) . Subsequently, 19 F imaging to map the intrarenal distribution of each type of NP was acquired using a fast spin-echo sequence (TR ¼ 2 s; echo spacing ¼ 9.2 ms; echo train length ¼ 8; nt ¼ 2048; spectral width ¼ 5760 Hz; slice thickness ¼ 2mm). The frequency offset was changed 5371 Hz between acquiring the CE and PFOB images.
Histological Assessment of Renal Injury
Following MRI, the formalin-fixed kidneys were embedded in paraffin, and sliced at 4-mm thickness for routine histological staining. The severity of tubular cell damage was evaluated in blinded fashion by a pathologist with specific expertise in renal histopathology (J.G.). Microscopic examination (4003) of histological stained slides was performed to identify and quantify features of tubular damage in the medulla, including tubular necrosis, tubular dilation, proximal tubular brush border fragmentation, and mitotic activity. These pathologic features were expressed as a percentage of all visualized tubules within five randomly selected high-powered fields per slide.
Fluorescence Microscopy of PFC NP
Fluorescent images of kidney cryosections were acquired to locate rhodamine-labeled PFOB NPs (red) and FITClabeled CE NPs (green), respectively. For each kidney, 2003 fluorescent images were acquired at five randomly selected positions in the medulla to determine colocalization of CE and PFOB NPs.
Statistics
Serum creatinine levels over time are expressed as mean 6 standard deviation. Acute tubular necrosis is expressed as mean 6 standard error of the mean. The concentration of trapped NPs in the kidney are expressed as mean 6 standard deviation. For comparisons of NP concentrations as measured by 19 F MRI, a Kruskal-Wallis H-test was used to determine whether one of the treatment groups was significantly different. Additional testing for individual comparisons was performed with the one-tailed MannWhitney test for two independent samples. P values are reported for both statistical tests. 
RESULTS
Post-AKI Effects of PPACK NPs
It was previously shown that rats pretreated with PPACK NP before transient AKI improves kidney functional recovery (15) . In this study, PPACK NPs were administrated after AKI, and the effect on renal function was monitored over time. Figure 2a plots the serum creatinine levels normalized by body weight serially through 7 days after AKI. In all animals, serum creatinine levels increased as early as 6 h after reperfusion, and peaked at 6 h (3.78 6 0.95 versus 4.31 6 1.11, control versus treated, respectively; P ¼ 0.25). The temporal evolution of kidney function in the PPACK NP-treated group did not differ significantly from that of the control (plain NP) group. The sham surgery group maintained physiological serum creatinine values throughout the recovery period. The effect of AKI and PPACK NP after treatment on tissue architecture was evaluated by an expert renal pathologist (J.G.) in kidneys that were allowed to recover for 7 days after AKI. Blinded scoring for necrotic tubular cells (Fig.  2b) was performed according to the described methodology. No significant difference (P ¼ 0.56) was identified between plain NP treatment (24% 6 11%) and PPACK NP treatment (20% 6 7%) groups at this time point, as seen in Figures 2c and 2d , respectively. The normal kidneys from the sham procedure showed no signs of tubular necrosis or injury.
Nanoparticle Trapping Before and After AKI
To determine whether differences existed in access of pre-versus posttreatment PFC NP regarding either localization or concentration, we pretreated a group of rats with PFOB NP, followed by AKI, and then post-AKI with CE NPs. Animals were euthanized 3 h after AKI and systemically perfused with saline to wash out circulating NPs, leaving NPs trapped in non-reperfused vascular territories (either extravasated or in microthrombi) for 19 F detection. 19 F MRI was used to quantitatively map the trapped PFOB and CE NPs, as described previously (13) . Figure 3a illustrates an overlay of the 19 F images atop a 1 H kidney image. In Figure 3b , a 1 H image of an injured kidney, the inner medulla of the injured kidney exhibited an abnormally low 1 H signal (shorter T Ã 2 times) as a likely consequence of blood accumulation in the microvasculature (30, 31) . Correspondingly, the 19 F image of both pretreated PFOB NPs (Fig. 3c, red) and posttreated CE NPs (Fig. 3d, green) showed trapping of both types of NPs (Fig. 3a , combined into yellow) in the inner medulla of the injured kidneys.
To depict the role of molecular targeting of PFC NPs in medullary trapping, Figure 3e demonstrates ). Additional statistical analysis with a one-tailed Mann-Whitney test for two independent variables confirmed that the control and PPACK groups were significantly different (P < 0.03) than the sham surgery group. The sham group exhibited a small amount of NPs that were not washed out of the kidney. These NPs were evenly dispersed at low levels throughout the kidney, as seen by 19 F MRI (not shown), and did not change in quantity from 3 h to 7 days (Fig. 3e) .
Accumulation of blood (hemorrhage) was observed by light microscopy in the AKI kidney image in Figure 4 . For the sham surgery procedure, no visual evidence of blood was observed by light microscopy. This hemorrhagic region appears as the low 1 H MRI signal in Figure  3b , and the correlated NP trapping is illustrated in Figures 3c and 3d . Figure 5 correlates the quantity of trapped pretreated NPs versus that of trapped posttreated NPs at 3 h after AKI. Here, one group of rats was pretreated with CE NPs and posttreated with PFOB NPs (filled circles). A second group of rats (open squares) had the regimens reversed by pretreating with PFOB NPs and then posttreating with CE NPs. These data illustrate linear correlations in both cases (r ¼ 0.99 for CE pretreatment and r ¼ 0.96 for PFOB pretreatment). Note, however, that the slope for the PFOB pretreated regimen (2.04) exceeds that for the CE pretreatment regimen (1.22), indicating that when PFOB is given first, there is relatively more posttreatment CE left after 3 h of reperfusion (i.e., a greater ratio/ slope (squares)) than if PFOB is given last (circles). This may be explained in part by the known faster tissue clearance rate for PFOB (tissue half-life of 4 days) (17,32-34) than for CE ($100 days) (32) (33) (34) . This evidence for NP clearance would be qualitatively consistent with the apparent clearance of pretreatment CE NPs noted in Figure 3e over the 7-day interval.
Kidney Dysfunction Reflects the Extent of Vascular Damage
We have shown previously that 19 F NP trapping quantitatively reflects microvascular damage in mouse models FIG. 5. Nanoparticle treatments given before and after AKI are linearly correlated. Quantitative 19 F MRS was used to measure the concentration of trapped NPs. Pretreatment NPs were injected 30 min before occlusion of the kidney, and posttreatment NPs were injected during reperfusion of the kidney. The filled circles represent rats with CE-core NPs used as the pretreatment and PFOB-core NPs given after AKI. The open squares represent rats given a pretreatment of PFOB-core NPs and CE-core NPs after AKI. The two groups were used to confirm that PFC differences did not affect the observations. Both groups are linearly correlated, indicating that NP trapping is the same for both particles after reperfusion. The NPs were given in a 2:1 pretreatment-to-posttreatment ratio, and this dose ratio was accounted for in this plot. of atherosclerosis (13, 14) . Figure 6 illustrates that the measured quantity of trapped NP in whole kidneys also correlates with kidney function in both pretreatment and posttreatment NP regimens (r ¼ 0.64 for both treatments). The overall quantity of trapped NPs in injured kidneys was determined by ex vivo 19 F MRS and normalized by the weight of kidney. The NP concentration is plotted for both the pre-and postinjury injections, which are compensated for the 2:1 pretreament-to-posttreatment administered dose ratio that was used to adjust for expected differences in signal intensity between PFOB and CE. Kidney function was measured as a change in serum creatinine concentration from baseline to the level observed at the time of euthanasia, 3 h after reperfusion.
Localization of Pre-and Posttreatment NP Trapping in Kidney Microvasculature Structures
Although the trapping of therapeutically inefficacious posttreated NPs in the inner medulla appears to be comparable to that of pretreated NPs by low-resolution MRI/ MRS criteria, Figure 7 indicates that NPs injected at two different time points are not entirely colocalized. Pretreatment particles (PFOB) labeled with rhodamine (red) and posttreatment particles (CE) labeled with FITC (green) sometimes colocalize (yellow-orange color), but are also observed situated in distinct regions (either pure red or green). Sham surgical procedures resulted in no detectable fluorescent signal for either type of NP.
DISCUSSION
The ability to quantitatively image vascular damage that occurs during AKI and through the extension phase can provide important pathophysiological insights into AKI (15, 35) . Toward this goal, for example, Kramman et al (4) recently extended the initial work of Advani et al (36) to implement a fluorescence microangiographic assay using perfusable micron-sized fluorescent beads coupled with algorithmic quantification of microscopic changes in renal peritubular capillaries (e.g., number density, caliber). They demonstrated a clear relationship between early renal injury (24 h after AKI) measured by elevated blood urea nitrogen, and later (8 weeks) capillary damage, suggesting that the initial ischemic insult to the microvasculature itself is a critical determinant of impaired renal function.
The current study proposes an alternative and potentially in vivo methodology to evaluate vascular damage in AKI that uses quantitative 19 F MRI readouts of molecular signatures emanating from perfluorocarbon NPs perfusing the kidney in vivo as a new option for imaging ischemic endothelial damage. Additionally, we sought to evaluate the use of the same NPs when functionalized to contain thrombin inhibitors as a novel theranostic approach for treating and monitoring AKI. We observed that the quantity of NPs trapped in kidneys after AKI was linearly correlated with the severity of kidney injury as measured by 19 F MRI, which suggests that this technique could be useful for noninvasive delineation of renal vascular damage (i.e., non-reperfusion). Local nonreperfusion in peritubular capillaries was apparent even after global reperfusion, which confirms that severe and persistent vascular damage occurs early during AKI, and ischemia persists as a likely cause of sustained regional hypoxia and tubular cell death. However, kidney functional recovery was not improved by post-AKI treatment with thrombin-inhibiting NPs, despite an earlier report from our group that pretreatment with the same therapeutic NPs was effective at preventing vascular damage and restoring nutritive perfusion to an extent (15) .
It has been proposed the "extension phase of ischemic injury" plays a critical role in AKI (1), manifested in part by persistent regional intrarenal non-reperfusion after the restoration of renal blood flow following transient ischemia (37) . Several factors could contribute to regional nonreperfusion, including (i) swelling of ischemically injured endothelial cells resulting in reduced capillary lumen size, which may block the passage of red blood cells, or even death and endothelial cell sloughing plugging capillary lumens; (ii) ischemia-induced inflammatory responses that recruit inflammatory cells, producing various factors such as superoxides that potentiate ongoing damage; (iii) an activated clotting cascade leading to thrombosis and vessel plugging. In this study, the 19 F MRI results revealed that NPs delivered either before or after AKI was induced could be observed in the cortico-medullary junction (Fig.  3) , where hemorrhage was observed as a direct consequence of vascular damage (Fig. 4) (also note the low T 1 -weighted signal on the T 1 -weighted images in Fig. 3b ). Minimal NP trapping was observed in the cortex, where the transient damage that occurs is readily reversed after kidney reperfusion (1) . Thus, the data indicate that NP trapping within the renal medulla is consistent regardless of the time point chosen for investigation. The MRI data indicate that the cortical regions are indeed better reperfused after AKI than are the cortico-medullary junction regions where sustained non-reperfusion is concentrated in the peritubular capillaries. In this region, severe hypoxia coupled with high energetic demands lead to disruption of vascular integrity (hemorrhage) and severe acute tubular damage. Accordingly, successful reperfusion of the cortex is not sufficient to restore renal function in this model, and the sustained non-reperfusion at the corticomedullary junction is responsible for renal dysfunction that recovers only slowly over time. Despite the apparent delivery of thrombin-targeted NPs to similar medullary regions, whether administered before or after AKI, the lack of treatment efficacy (Fig. 2a) suggest that thrombin's deleterious actions are too immediate for intervention by posttreatment therapeutics, even though thrombin is clearly a valid target. Pre-and posttreatment strategies appear to differ significantly in NP delivery kinetics, as evidenced by differences in microscopic trapping sites (Fig. 7) and quantities (Fig. 5) . The microscopic evidence of noncolocalized NP trapping suggests that smaller nutritive vessels may not be accessible after AKI, even if larger vessels admit NPs to the same general areas. This rapid onset of non-reperfusion may be one cause for widespread clinical failure of most therapies to interdict AKI when administered after injury.
Both PPACK-targeted and nontargeted NPs are trapped to the same extent (Fig. 3e) , indicating that molecular targeting of thrombin is not affecting the local deposition of the NPs, and that it is a passive event not requiring binding to a specific molecular tether to be retained in the injured medulla. The linear relationship between pre-and posttreatment trapping, seen in Figure 5 , suggests that passive intrarenal trapping evenly distributes the NP regardless of the time of treatment or the type of NP used for treatment. Altogether, this indicates that 19 F MRI of PFC NPs is able to depict the regional severity of medullary damage across a range of ischemic insults.
The presence of regional non-reperfusion after AKI might suggest that antithrombotic therapy could benefit kidney recovery by preventing non-reperfusion. In a previous study we showed that pre-AKI treatment with antithrombin PPACK NPs was effective in targeting and inhibiting thrombin activity as well as improving kidney functional recovery after AKI (15) . Other reports have also confirmed that antithrombin therapies with NP are able to improve kidney recovery (23) (24) (25) (26) (27) . For example, Sharfuddin in the Molitoris group (23) used recombinant thrombomodulin, a thrombin cofactor in the anticoagulation pathway of activated protein C, to improve kidney function in both pre-and posttreatment regimens. In this study, the posttreatment effect of PPACK NPs revealed no significant difference in renal recovery following AKI. The reason for the difference in outcomes between the two post-AKI treatment strategies may relate to the timing of the therapies, in our case delivered within a few minutes after restoration of flow, and in the Molitoris work, 2 h after reperfusion. It is possible that immediate thrombosis thwarted access of our PPACK NPs to sites of injury, as Enestrom et al showed clear evidence of extensive deposition of fibrinous clots in peritubular capillaries and vasa recta small vessel obstruction as early as 5 min after reperfusion, peaking at 15 min, all of which was preventable by heparin delivered before reperfusion (7) . These thrombi gradually dissipate by lysis over the following hour, perhaps allowing better access of the thrombomodulin to sites of injury 2 h later when occlusion was less prevalent, as contrasted with our case, in which earlier delivery of PPACK NPs would encounter more extensive thrombotic obstruction, affording less penetration.
Regarding mechanisms of NP accumulation in nonreperfused zones, because kidney damage and nonreperfusion evolves rapidly within 15 min (7), there is little possibility that uptake by circulating immune cells could be responsible for the observed NP trapping. Indeed, we have reported previously that no appreciable uptake of PFC NP by circulating white blood cells is notable within 30 min after injection (13) . In the present work, the 45-min occlusion time followed by non-reperfusion leaves little chance for immune cells to deliver any substantial influx of NPs (38) . The pretreatment particles are expected to be either extravasated or contained within microvascular thrombi (Figs. 2 and 5) , and the posttreatment particles appear to be capable of reaching the same general locations, although not into therapeutically relevant structures, as discussed previously.
Our previous report of the benefit of pretreatment with thrombin-inhibiting PPACK NPs (15) , together with the lack of efficacy of immediate post-AKI treatment in this study, argues that microvascular thrombosis due to activation of thrombin is clearly a high-value target for therapeutic intervention, but that it occurs too rapidly either during or after ischemic injury to prevent, once AKI is established. According to the careful examination of early thrombosis in AKI by Enestrom et al (7) , the actual ischemia times in AKI may be far greater than anticipated in experimental and clinical AKI, based on recorded occlusion times or periods of hypoperfusion. After clot dissolution, the vasculature might be "perfusable" to an extent, yet manifest severe endothelial damage sufficient to trap PFC NPs in an edematous interstitial compartment under conditions that would further compromise oxygen and nutrient flow to tubular cells well beyond the time of complete microvascular obstruction.
Previous MRI studies of AKI have used techniques such as the blood oxygenation level-dependent effect (39, 40) and arterial spin labeling to assess renal damage and abnormal perfusion (41) (42) (43) . The blood oxygenation level-dependent effect allows for a measure of renal tissue oxygen tension, which reveals initial and sustained hypoxic conditions in AKI. Arterial spin labeling allows for measurement of regional perfusion within the kidney. We reported previously that renal perfusion can be delineated in vivo by 19 F MRI with PFC NPs (15) , and that tissue deposition of PFC NP can be quantified on clinical 3T imaging platforms (13) . An advantage of this approach is the ability to delineate quantitatively the absolute volume of the damaged and non-reperfused vascular territories according to the trapped 19 F signal, despite apparent global reperfusion with a nonrenotoxic contrast agent. The quantitative results obtained with 19 F MRI of PFC NPs suggest that NP trapping as a result of microvascular damage is correlated with acute kidney dysfunction and could therefore serve as a potential proxy for vascular disruption if confirmed in more extensive studies.
Previous studies have examined 19 F MRI of PFC NPs that are molecularly targeted to sites of thrombosis (28, 44) . These studies indicate the potential of thrombintargeted NPs to serve as theranostic agents that both inhibit and image developing thrombi with the use of specific 19 F MRI signatures. Although we have reported previously that thrombin-targeted NPs are useful for improving kidney function after AKI when administered before ischemic events, here we report that thrombintargeted NPs do not enhance recovery of kidney function when administered after ischemic injury, as a result of the rapid onset of the non-reperfusion condition. Nevertheless, the extent of non-reperfusion can be depicted by 19 F MRI, which offers a potentially noninvasive and quantifiable method for evaluating the severity of regional renal damage after AKI. In summary, our data suggest that the ability of 19 F spectroscopy and imaging to depict the regional severity of barrier disruption with a quantitative metric that is directly correlated with the severity of renal injury (Figs. 3 and 5) offers a nonnephrotoxic approach to assessing vascular injury and healing that accompany recovery of kidney function after AKI. Early post-AKI treatment with antithrombin PPACK NPs did not improve kidney functional recovery, likely due to poor access of agents to the obstructed microvasculature. These observations taken together suggest a cautionary message: The prolongation of regional medullary ischemia for hours beyond reperfusion renders corticomedullary tubular structures susceptible to continued necrosis despite restoration of large vessel flow, which suggests that there may be significant limitations to acute interventions after AKI, such as thrombin inhibition, which are proposed to interdict renal tubular damage. These considerations argue for alternative therapeutic approaches that might focus more on restoring vascular integrity beyond the acute phases of ischemic kidney injury.
